Search

Your search keyword '"Sardella, C"' showing total 164 results
Start Over Author "Sardella, C"
164 results on '"Sardella, C"'

28. La costellazione di urbanità

Author

Valentini, A., Pili, S., Armieri, F. P., Sardella, C., Tombolini, I., Valente, Lavinia, and Veisz, A.

Subjects
progettazione, Workshop, costellazione
Published
2017

29. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey

Author

Claudio, Velati, Luisa, Romano, Laura, Fomiatti, Lorella, Baruffi, Alessandro Remo Zanetti, Research Group: Sciariada, Simti L., Lobbiani, L., Prati, D., Marconi, M., Ravagnani, E., Rossi, E., Rossini, S., Bellavita, P., Moroni, G. A., Bodini, U., Pagliaro, P., Azzario, F., Rossi, D., Sciorelli, G., Salvaneschi, L., Cambie, G., Marini, M., Pizzoccolo, G., Gazzola, G. B., Peres, E., Mariottini, C., Graziani, G., Baicchi, U., Palla, P., Vacri, L., Strada, P., Miceli, M., Iudicone, P., Girelli, Gabriella, Ursitti, A., De Silvestro, G., Gentile, R., Di Paola, P., Manca, M., Martinelli, L., Bonomo, P., Calabrese, S., Pistolese, G., Aprili, G., Bressan, F., Ripamonti, M., Catalano, A., Gallerano, P., Giacalone, I., Fiorilla, A., Giannotti, G., Cantella, R., Di Persia, M. G., Esposito, V., Sardella, C., Di Monte, D., Bajorek, M., Reina, A., Silvani, C. M., Piani, M., Salvoni, G., De Felice, L., Macri, M., De Palma, M., Vecchi, C., Belloni, M., Bettini, C., Ghiazza, P., De Santis, D., Di Mauro, L., Antoncecchi, S., Rinaldi, C., Allegreita, G., Siracusano, L., Adami, R., Lanteri, M., Mazzei, C., Tagariello, G., Gajo, G. B., Berti, P., Giordano, C., Palazzesi, G., Del Gusto, B., Pavone, A., Vacchini, M., Tomasini, A., Vaselli, G., Fiorin, F., Bresolin, G., Bertola, F., Testa, D., Semino, G., Tomasini, I., Zucchelli, P., Chicchi, R., Peano, G., Franchi, D., Sabelli, M., Miloro, G., Di Gregorio, P., Reimondo, P., Cimino, G., Tripodi, G., Borzini, P., Tarditi, M., Cocchi, T., Pata, V., Santarelli, R., Geremicca, W., Minerva, A., Maccarione, F. P., Solanda, F., Rivasi, P., Carubia, F., Prinoth, O., Ostuni, A., Bossio, M., Maggiotto, A., Valentino, F., Puzzonia, P., and Source Musto, C.

Subjects
Adult, Male, Hepatitis B virus, Genotype, Hepacivirus, Hepatitis C virus, Immunology, Blood Donors, HIV Infections, medicine.disease_cause, Virus, Flaviviridae, Orthohepadnavirus, Risk Factors, Seroepidemiologic Studies, medicine, Humans, Mass Screening, Immunology and Allergy, Aged, biology, business.industry, HIV, virus diseases, Hematology, Middle Aged, Hepatitis B, biology.organism_classification, medicine.disease, Hepatitis C, Virology, digestive system diseases, Italy, Hepadnaviridae, Virus Diseases, Health Care Surveys, Blood Banks, Female, Morbidity, Safety, business, Risk Reduction Behavior
Abstract

BACKGROUND: Nucleic acid testing (NAT) for hepatitis C virus (HCV) and human immunodeficiency virus (HIV) has been implemented in several European countries and in the United States, while hepatitis B virus (HBV) NAT is still being questioned by opinions both in favor and against such an option, depending on the HBV endemicity, health care resources, and expected benefits. STUDY DESIGN AND METHODS: This survey was aimed to assess the NAT impact in improving the safety of blood supply in Italy, 6 years after implementation. The study involved 93 Italian transfusion centers and was carried out in 2001 through 2006. A total of 10,776,288 units were tested for the presence of HCV RNA, 7,932,430 for HIV RNA, and 3,405,497 for HBV DNA, respectively. RESULTS: Twenty-seven donations or 2.5 per million tested were HCV RNA–positive/anti-HCV–negative; 14 or 1.8 per million units tested were HIV RNA–positive/anti-HIV–negative; and 197 or 57.8 per million donations tested were HBV DNA–positive/hepatitis B surface antigen–negative. Of the latter, 8 (2.3/106) were collected from donors in the window phase of infection and 189 (55.5/106) from donors with occult HBV. Sixty-eight percent of the latter donors had hepatitis B surface antibody, 74.5 percent of whom with concentrations considered protective (≥10 mIU/mL). CONCLUSION: NAT implementation has improved blood safety by reducing the risk of entering 2.5 HCV and 1.8 HIV infectious units per million donations into the blood supply. The yield of NAT in detecting infectious blood before transfusion was higher for HBV than for HCV or HIV. However, the benefit of HBV NAT in terms of avoided HBV-related morbidity and mortality in blood recipients needs to be further evaluated.

Published
2008

30. Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis

Author

PAOLO SIMIONI, Prandoni, P., Lensing, A. W. A., Manfrin, D., Tormene, D., Gavasso, S., Girolami, B., Sardella, C., Prins, M., Girolami, A., Infectious diseases, AII - Amsterdam institute for Infection and Immunity, and APH - Amsterdam Public Health

Subjects
Adult, Aged, 80 and over, Male, Venous Thrombosis, Heterozygote, Immunology, Factor V, Cell Biology, Hematology, Middle Aged, Biochemistry, Cohort Studies, Recurrence, Risk Factors, Thromboembolism, Mutation, Prevalence, Humans, Female, Prothrombin, Aged, Follow-Up Studies, Retrospective Studies
Abstract

Carriers of a mutation in the prothrombin (clotting factor II) or factor V gene have a 2- to 4-fold greater risk for venous thromboembolism than subjects without the mutations. Whether both mutations also predispose to recurrent venous thromboembolism is unclear. Outpatients who had a first episode of proven symptomatic deep-vein thrombosis and a long-term follow-up were studied. The outcome measure was the cumulative incidence of confirmed venous thromboembolic complications. Two hundred fifty-one patients were enrolled in the study. Mean duration of follow-up was 8.3 years. The prothrombin gene mutation was demonstrated in 27 patients (prevalence, 10.8%; 95% CI, 6.9 to 14.6), and the factor V gene mutation was demonstrated in 41 patients (prevalence, 16.3%; 95% CI, 11.8 to 20.9). The cumulative incidence of venous thromboembolic complications after 10 years was 61.3% (95% CI, 35.7 to 87.9), and the hazard ratio was 2.4 (95% CI, 1.3 to 4.7; P = .004) in patients with the prothrombin gene mutation); the cumulative incidence of venous thromboembolic complications after 10 years was 55.2% (95% CI, 36.4 to 74.0), and the hazard ratio was 2.4 (95% CI, 1.4 to 4.1;P = .001) in patients with the factor V gene mutation. In comparison, the cumulative incidence of venous thromboembolic complications after 10 years was 23.1% (95% CI, 16.2 to 30.1) in patients without the mutations. Prothrombin and factor V gene mutations occur frequently in patients with venous thrombosis and are associated with an increased risk for recurrent venous thromboembolic complications

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results